These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

631 related items for PubMed ID: 23353698

  • 1. ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation.
    Russo M, Spagnuolo C, Volpe S, Tedesco I, Bilotto S, Russo GL.
    Biochem Pharmacol; 2013 Apr 01; 85(7):927-36. PubMed ID: 23353698
    [Abstract] [Full Text] [Related]

  • 2. Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.
    Tromp JM, Geest CR, Breij EC, Elias JA, van Laar J, Luijks DM, Kater AP, Beaumont T, van Oers MH, Eldering E.
    Clin Cancer Res; 2012 Jan 15; 18(2):487-98. PubMed ID: 22128299
    [Abstract] [Full Text] [Related]

  • 3. CK2 and PI3K are direct molecular targets of quercetin in chronic lymphocytic leukaemia.
    Russo M, Milito A, Spagnuolo C, Carbone V, Rosén A, Minasi P, Lauria F, Russo GL.
    Oncotarget; 2017 Jun 27; 8(26):42571-42587. PubMed ID: 28489572
    [Abstract] [Full Text] [Related]

  • 4. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
    Hikita H, Takehara T, Shimizu S, Kodama T, Shigekawa M, Iwase K, Hosui A, Miyagi T, Tatsumi T, Ishida H, Li W, Kanto T, Hiramatsu N, Hayashi N.
    Hepatology; 2010 Oct 27; 52(4):1310-21. PubMed ID: 20799354
    [Abstract] [Full Text] [Related]

  • 5. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation.
    Kang MH, Wan Z, Kang YH, Sposto R, Reynolds CP.
    J Natl Cancer Inst; 2008 Apr 16; 100(8):580-95. PubMed ID: 18398104
    [Abstract] [Full Text] [Related]

  • 6. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
    Iacovelli S, Ricciardi MR, Allegretti M, Mirabilii S, Licchetta R, Bergamo P, Rinaldo C, Zeuner A, Foà R, Milella M, McCubrey JA, Martelli AM, Tafuri A.
    Oncotarget; 2015 Oct 13; 6(31):32089-103. PubMed ID: 26392332
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The pleiotropic flavonoid quercetin: from its metabolism to the inhibition of protein kinases in chronic lymphocytic leukemia.
    Russo GL, Russo M, Spagnuolo C.
    Food Funct; 2014 Oct 13; 5(10):2393-401. PubMed ID: 25096193
    [Abstract] [Full Text] [Related]

  • 9. N-(4-hydroxyphenyl)retinamide promotes apoptosis of resting and proliferating B-cell chronic lymphocytic leukemia cells and potentiates fludarabine and ABT-737 cytotoxicity.
    Bruno S, Ghiotto F, Tenca C, Mazzarello AN, Bono M, Luzzi P, Casciaro S, Recchia A, Decensi A, Morabito F, Fais F.
    Leukemia; 2012 Oct 13; 26(10):2260-8. PubMed ID: 22475870
    [Abstract] [Full Text] [Related]

  • 10. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.
    Rooswinkel RW, van de Kooij B, Verheij M, Borst J.
    Cell Death Dis; 2012 Aug 09; 3(8):e366. PubMed ID: 22875003
    [Abstract] [Full Text] [Related]

  • 11. The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.
    Paoluzzi L, Gonen M, Bhagat G, Furman RR, Gardner JR, Scotto L, Gueorguiev VD, Heaney ML, Manova K, O'Connor OA.
    Blood; 2008 Oct 01; 112(7):2906-16. PubMed ID: 18591385
    [Abstract] [Full Text] [Related]

  • 12. ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents.
    Touzeau C, Dousset C, Bodet L, Gomez-Bougie P, Bonnaud S, Moreau A, Moreau P, Pellat-Deceunynck C, Amiot M, Le Gouill S.
    Clin Cancer Res; 2011 Sep 15; 17(18):5973-81. PubMed ID: 21821698
    [Abstract] [Full Text] [Related]

  • 13. Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737.
    Lucas KM, Mohana-Kumaran N, Lau D, Zhang XD, Hersey P, Huang DC, Weninger W, Haass NK, Allen JD.
    Clin Cancer Res; 2012 Feb 01; 18(3):783-95. PubMed ID: 22173547
    [Abstract] [Full Text] [Related]

  • 14. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
    Simonin K, N'Diaye M, Lheureux S, Loussouarn C, Dutoit S, Briand M, Giffard F, Brotin E, Blanc-Fournier C, Poulain L.
    Apoptosis; 2013 Apr 01; 18(4):492-508. PubMed ID: 23344663
    [Abstract] [Full Text] [Related]

  • 15. The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.
    Pétigny-Lechartier C, Duboc C, Jebahi A, Louis MH, Abeilard E, Denoyelle C, Gauduchon P, Poulain L, Villedieu M.
    Mol Cancer Ther; 2017 Jan 01; 16(1):102-115. PubMed ID: 27980105
    [Abstract] [Full Text] [Related]

  • 16. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.
    Konopleva M, Milella M, Ruvolo P, Watts JC, Ricciardi MR, Korchin B, McQueen T, Bornmann W, Tsao T, Bergamo P, Mak DH, Chen W, McCubrey J, Tafuri A, Andreeff M.
    Leukemia; 2012 Apr 01; 26(4):778-87. PubMed ID: 22064351
    [Abstract] [Full Text] [Related]

  • 17. Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics.
    Choudhary GS, Tat TT, Misra S, Hill BT, Smith MR, Almasan A, Mazumder S.
    Oncotarget; 2015 Jul 10; 6(19):16912-25. PubMed ID: 26219338
    [Abstract] [Full Text] [Related]

  • 18. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer.
    Wesarg E, Hoffarth S, Wiewrodt R, Kröll M, Biesterfeld S, Huber C, Schuler M.
    Int J Cancer; 2007 Dec 01; 121(11):2387-94. PubMed ID: 17688235
    [Abstract] [Full Text] [Related]

  • 19. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms.
    Kuroda J, Kimura S, Andreeff M, Ashihara E, Kamitsuji Y, Yokota A, Kawata E, Takeuchi M, Tanaka R, Murotani Y, Matsumoto Y, Tanaka H, Strasser A, Taniwaki M, Maekawa T.
    Br J Haematol; 2008 Jan 01; 140(2):181-90. PubMed ID: 18028486
    [Abstract] [Full Text] [Related]

  • 20. An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737.
    Al-Harbi S, Hill BT, Mazumder S, Singh K, Devecchio J, Choudhary G, Rybicki LA, Kalaycio M, Maciejewski JP, Houghton JA, Almasan A.
    Blood; 2011 Sep 29; 118(13):3579-90. PubMed ID: 21772052
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.